Every material Form 8-K VivoSim Labs, INC. has filed with the SEC since August 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 13, 2026, subsidiary Organovo, Inc. signed a Second Amendment to its lease for the company's principal executive offices at 11555 Sorrento Valley Road, San Diego, with San Diego Inspire 2, LLC. The amendment reduces the leased space, extends the term for Suite 100 through April 30, 2028, and sets a temporary rent abatement, and the filing does not state a financial impact on the company beyond these lease terms.
Company must vacate and surrender Suite 202 on or before February 28, 2027
Term for Suite 100 extended from March 1, 2027 through April 30, 2028
Monthly base rent adjusted to $43,072.85
Rental abatement of $21,536.43 per month from March 1, 2027 through June 30, 2027, totaling $86,145.70
At its September 30, 2026 annual meeting, VivoSim Labs stockholders elected Keith Murphy and Adam Stern as Class III directors and approved a reverse stock split, at a ratio between 1-to-5 and 1-to-20 set by the Board, that can take effect until September 30, 2027. Stockholders also approved adding 3,165,000 shares to the equity incentive plan and approved issuing shares on warrant exercises and cutting the exercise price of 2024 warrants from $9.60 to $0.85, which may affect existing holders' ownership.
Annual meeting held September 30, 2026; 6,180,635 shares, or 37.26% of 16,586,495 outstanding shares, were represented.
Reverse stock split approved at a 1-to-5 to 1-to-20 ratio, to be set by the Board on or before September 30, 2027, with 74.12% of votes cast in favor.
Equity incentive plan increase of 3,165,000 shares approved with 72.52% of votes cast in favor.
Warrant approvals cover up to 4,705,883 shares and reduce the exercise price of May 13, 2024 warrants from $9.60 to $0.85 per share.
VivoSim Labs (VIVS) received a Nasdaq notice on August 17, 2026 saying its stock no longer met the $1 minimum bid price over 30 consecutive business days. The company has 180 calendar days, until February 16, 2027, to regain compliance, and its shares continue to trade on the Nasdaq Capital Market for now. The company has proposed a reverse stock split, which requires stockholder approval, and a failure to regain compliance could lead to delisting proceedings.
Nasdaq notice received August 17, 2026 under Listing Rule 5550(a)(2) for the $1 minimum bid price
Compliance deadline is February 16, 2027; regaining it requires a closing bid of at least $1 for ten consecutive business days
Proposed reverse stock split ratio range of 1-for-5 to 1-for-20, subject to stockholder approval in the 2026 annual meeting proxy
Notice has no immediate effect on listing or trading; ticker remains VIVS
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every VivoSim Labs, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →